Slides
Page 1
Q3 2026 Results Gael Touya, Aptar President and CEO Vanessa Kanu, Executive Vice President and CFO
Page 2
This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management’s beliefs and assumptions in lightof information currently available to management. Accordingly, the Company’s actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in the Company’s operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such statements to reflect new events, information or circumstances after the date of this presentation. During the course of this presentation, certain non-GAAP financial information will be presented. Refer to the Appendix at the end of this presentation for additional information and a reconciliation to the most directly comparable GAAP measures. However, we are not able to reconcile forward-looking non-GAAP financial measures because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates andchanges in the fair value of equity investments, or reliably predicted without unreasonable effort because they are not part of the company's routine activities,such as restructuring and acquisition costs. The variability of these items could have a significant impact on our future GAAP financial results. We present earnings before net interest and taxes (“EBIT”), earnings before net interest, taxes, depreciation and amortization (“EBITDA”) and adjusted earnings per share. We also present our adjusted earnings before net interest and taxes (“Adjusted EBIT”), adjusted earnings before net interest, taxes, depreciation and amortization (“Adjusted EBITDA”) and adjusted earnings per share, all of which exclude restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments, gain from remeasurement of equity method investment, net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Russia deconsolidation impacts comprise the loss on deconsolidation of our Russian subsidiary and related receivable reserves and legal costs, which we exclude because they resulted from a governmental action rather than from the operations of our businesses. Prior-year adjusted earnings per share are presented at current-period foreign currency exchange rates. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. For the three and nine months ended September 30, 2026 and 2025 and for the year ended December 31, 2025, “other special items” include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc. involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to "Legal Proceedings" within Note 13 - Commitments and Contingencies within Aptar's Form 10-K for the year ended December 31, 2025 and subsequent SEC filings. Our Operations Outlook is also provided on a non-U.S. GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives, acquisition-related costs and other special items. Core sales exclude acquisitions and changes in foreign currency sales and, for the three and nine months ended September 30, 2026, the net sales of our Russian subsidiary from both periods. Core sales growth is calculated as current-period core sales less prior-period core sales, divided by prior-period core sales multiplied by a hundred. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. Return on Invested Capital (ROIC) is calculated as Adjusted Earnings before Net Interest and Taxes, less Tax Effect / Average Capital, whereas Average Capital is the average of beginning-of-year and end- of-year Capital, and Capital is Equity plus Debt less Cash and short-term investments. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. F O R W A R D - L O O K I N G S T A T E M E N T S A N D N O N - G A A P F I N A N C I A L M E A S U R E S 2
Page 3
Financial Highlights Q 3 2 0 2 6 • Delivered broad-based revenue growth across all three segments • Pharma delivered impressive growth in central nervous system therapies, pulmonary, injectables and consumer healthcare, while maintaining profitability at the high end of our long-term target range • Our Pharma pipeline remains strong, with continued focus on building the pipeline and converting opportunities into future growth • New technologies and development programs are expanding the role we can play with customers across the drug development cycle • Beauty and Closures also delivered strong top-line growth, including double-digit core sales growth in Closures, where innovation in beverage dispensing continues to gain momentum 6% Q3 Reported Sales Growth 5% Q3 Core Sales Growth* $0.51 Q3 Reported Earnings Per Share, impacted by deconsolidation of the Russian subsidiary $1.52 Q3 Adjusted Earnings Per Share* * See accompanying slide titled “Forward-Looking Statements & Non-GAAP Financial Measures” for definition and Appendix for reconciliation, as applicable, to the most directly comparable GAAP measure. 3
Page 4
• Encouraged by early clinical study of Beat the Blink , which showed strong patient acceptance and preference for the solution. Part of an exclusive collaboration with Bausch + Lomb. • Recent example of moving from Rx-to-OTC is in the acne space where our pump technology is supporting its transition from prescription to over- the-counter in the U.S • Research collaboration with Massachusetts General Hospital focused on advancing the science of nose-to-brain delivery • LuerVax® intranasal delivery system and Spray Divider now carrying the European Conformity mark, expanding our ability to support customers developing intranasal vaccines • Three-year research collaboration with Macquarie University focused on high-dose dry powder delivery of biologic medicines using Orbital platform • Expanding respiratory platform through the acquisition of PULMOTREE, adding its Kolibri non-propellant liquid inhaler technology • Launched Premia Precision, new quality standard for elastomer components designed for complex and high-value injectable therapies, including biologics and GLP-1 medicines • Collaborating with Stevanato Group to advance system-level solutions that help customers make earlier, more informed packaging decisions for complex biologics and other injectable therapies P H A R M A P I P E L I N E D E V E L O P M E N T 4 Research Collaboration with Massachusetts General Hospital LuerVax® intranasal delivery system and Spray Divider Orbital Platform for Research Collaboration with Macquarie University Kolibri non-propellant liquid inhaler technology Premia Precision, new quality standard for elastomer components Collaboration with Stevanato Group to Help Accelerate Pre-Filled Syringe System Selection Beat the Blink Rx-to-OTC switch in acne space, with Aptar pump
Page 5
S P E A K E R S PureHale® technology for NeilMed saline mist Closure with SimpliSqueeze® valve for Hormel Foods’ Wholly Guacamole Activ-Film technology used in capsule treatment of invasive fungal infections First launch of patented fragrance- refill technology with BVLGARI’s Le Gemme Tygar Travel Spray Premium cosmetic pump on Helena Rubinstein’s Powercell Serum Custom pump for SK-II Facial Treatment Serum SimpliSqueeze® valve technology for inverted Dance Body Wash by IP One P R O D U C T A N D T E C H N O L O G Y H I G H L I G H T S 5 Two-color, easy open closure for McCormick spices P H A R M A B E A U T Y C L O S U R E S
Page 6
Reported Results Q 3 2 0 2 6 * See accompanying slide titled “Forward-Looking Statements & Non-GAAP Financial Measures” for definition and Appendix for reconciliation, as applicable, to the most directly comparable GAAP measure. 6 0% Currency Effects +1% Acquisitions / Deconsolidation +5% Core Sales Growth* $961 $1,019 $- $200 $400 $600 $800 $1,000 $1,200 Q3 2025 Q3 2026 Q3 Reported Sales (in millions $) 6% 17.1% Reported Effective Tax Rate Q3 2025 45.6% Reported Effective Tax Rate Q3 2026 Impacted by $0.94 from the deconsolidation of the Russian subsidiary $1.92 $0.51 $- $0.50 $1.00 $1.50 $2.00 $2.50 Q3 2025 Q3 2026 Q3 Reported EPS -73%
Page 7
Adjusted EPS and Adjusted EBITDA Q 3 2 0 2 6 * See accompanying slide titled “Forward-Looking Statements & Non-GAAP Financial Measures” for definition and Appendix for reconciliation, as applicable, to the most directly comparable GAAP measure. 7 20.8% Effective Tax Rate Adjusted Earnings* Q3 2025 23.4% Effective Tax Rate Adjusted Earnings* Q3 2026 $1.62 $1.52 $- $0.20 $0.40 $0.60 $0.80 $1.00 $1.20 $1.40 $1.60 $1.80 Q3 2025 Q3 2026 Q3 Adjusted EPS -6% $223 $217 $- $40 $80 $120 $160 $200 $240 $280 Q3 2025 Q3 2026 Q3 Adjusted EBITDA (in millions $) -2%
Page 8
Reported Results Y E A R - TO - D A T E 2 0 2 6 * See accompanying slide titled “Forward-Looking Statements & Non-GAAP Financial Measures” for definition and Appendix for reconciliation, as applicable, to the most directly comparable GAAP measure. 8 $2,814 $3,028 $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 YTD 2025 YTD 2026 YTD Reported Sales (in millions $) 8% +4% Currency Effects +2% Acquisitions / Deconsolidation +2% Core Sales Growth* 20.4% Reported Effective Tax Rate YTD 2025 28.1% Reported Effective Tax Rate YTD 2026 $4.75 $3.00 $- $0.50 $1.00 $1.50 $2.00 $2.50 $3.00 $3.50 $4.00 $4.50 $5.00 YTD 2025 YTD 2026 YTD Reported EPS -37% Impacted by $0.94 from the deconsolidation of the Russian subsidiary
Page 9
Adjusted EPS and Adjusted EBITDA Y E A R - TO - D A T E 2 0 2 6 * See accompanying slide titled “Forward-Looking Statements & Non-GAAP Financial Measures” for definition and Appendix for reconciliation, as applicable, to the most directly comparable GAAP measure. 9 $624 $619 $- $100 $200 $300 $400 $500 $600 $700 $800 YTD 2025 YTD 2026 YTD Adjusted EBITDA (in millions $) -1% $4.60 $4.13 $- $0.50 $1.00 $1.50 $2.00 $2.50 $3.00 $3.50 $4.00 $4.50 $5.00 YTD 2025 YTD 2026 YTD Adjusted EPS -10% 21.9% Effective Tax Rate Adjusted Earnings* YTD 2025 23.2% Effective Tax Rate Adjusted Earnings* YTD 2026
Page 10
Pharma Results Q 3 2 0 2 6 * See accompanying slide titled “Forward-Looking Statements & Non-GAAP Financial Measures” for definition and Appendix for reconciliation, as applicable, to the most directly comparable GAAP measure. 10 $445 $454 $- $50 $100 $150 $200 $250 $300 $350 $400 $450 $500 Q3 2025 Q3 2026 Q3 Sales Reported Core Acquisitions / Deconsolidation Currency Effects 2% 1% 2% -1% (in millions $) 37.2% 36.4% 0% 10% 20% 30% 40% Q3 2025 Q3 2026 Adjusted EBITDA Margin % 70% 20% 10% Proprietary Drug Delivery Systems* Injectables Active Material Science Solutions Sales by Market (YTD 2026) **Proprietary Drug Delivery Systems includes Prescription, Consumer Health Care, and Digital Health Markets * *
Page 11
12.1% 11.4% 0% 2% 4% 6% 8% 10% 12% 14% 16% Q3 2025 Q3 2026 Adjusted EBITDA Margin % Beauty Results Q 3 2 0 2 6 * See accompanying slide titled “Forward-Looking Statements & Non-GAAP Financial Measures” for definition and Appendix for reconciliation, as applicable, to the most directly comparable GAAP measure. 11 Sales by Market (YTD 2026)* $328 $357 $- $40 $80 $120 $160 $200 $240 $280 $320 $360 $400 Q3 2025 Q3 2026 Q3 Sales Reported Core Acquisitions Currency Effects 9% 8% 1% 0% (in millions $) 59% 36% 5% Fragrance and Facial skincare Personal Care Home Care
Page 12
Closures Results Q 3 2 0 2 6 12 Sales by Market (YTD 2026) $188 $208 $- $20 $40 $60 $80 $100 $120 $140 $160 $180 $200 $220 Q3 2025 Q3 2026 Q3 Sales Reported Core Acquisitions / Deconsolidation Currency Effects 11% 11% -1% 1% (in millions $) 16.1% 15.5% 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% Q3 2025 Q3 2026 Adjusted EBITDA Margin % 48% 29% 15% 8% Food Beverage Personal Care Other **Other includes Beauty and Home Care markets * See accompanying slide titled “Forward-Looking Statements & Non-GAAP Financial Measures” for definition and Appendix for reconciliation, as applicable, to the most directly comparable GAAP measure. ** *
Page 13
Outlook Q 4 2 0 2 6 • Expect Aptar to finish the year strong, supported by continued Pharma growth, particularly in consumer healthcare and Injectables and without the headwind from emergency medicine destocking • Our Pharma pipeline remains strong, with new technologies and development programs expanding our reach across therapeutic areas and advancing opportunities for future growth • Closures continues its great momentum, with innovation helping drive increased demand, particularly for our beverage technologies • In Beauty, we remain focused on improving our long-term North American trajectory, while we continue to see pockets of healthy demand in areas, such as prestige fragrance, globally $1.13 $1.22 $1.39 – $1.47 $0.00 $0.20 $0.40 $0.60 $0.80 $1.00 $1.20 $1.40 $1.60 $1.80 Q4 2025 Reported Q4 2025 Adjusted* Q4 2026 Adjusted* Earnings Per Share * See accompanying slide titled “Forward-Looking Statements & Non-GAAP Financial Measures” for definition and Appendix for reconciliation, as applicable, to the most directly comparable GAAP measure. 13
Page 14
A G E N D A 14 Q 4 / F Y 2 0 2 6 Key Highlights Effective Tax Rate 17.5% to 19.5% for Q4 2026 Prior year Q4 comparable adjusted effective tax rate = 19.4% Currency Guidance (Euro) 1.12 for Q4 2026 Assuming a Euro to USD Exchange Rate CapEx Range for Full Year 2026 $260 to $280 million Net of any government grants, with the majority of capital allocated toward our pharma segment Depreciation and Amortization Range for Full Year 2026 $310 to $320 million Including recently closed acquisitions, timing of capitalization of assets and FX Full Year (Expected) Quarterly (Expected)
Page 15
Appendix 15
Page 16
16 Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands)
Page 17
17 Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands)
Page 18
18 Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands)
Page 19
19 Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands)
Page 20
20 Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data)
Page 21
21 Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data)
Page 22
22 Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data)
Page 23
23 Reconciliation of Reported to Core Sales Growth by Market (Rounded to the nearest whole percent)
Page 24
24 Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands)
Page 25
25 Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands)
Page 26
26 Reconciliation of Adjusted EBIT After Taxes to Net Income (Unaudited) ($ In Thousands)
Page 27
27 Reconciliation of Capital to Stockholders’ Equity (Unaudited) ($ In Thousands)
Page 28
28 Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands)
Page 29
29 Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands)
Page 30
30 Supplemental Information